CSL Behring: A Global Leader in Plasma-Derived Therapies

Headquartered in King of Prussia, Pennsylvania, United States, CSL Behring is a global biopharmaceutical leader that specializes in plasma-derived therapies and operates in over 30 countries worldwide. The company is dedicated to providing life-saving treatments for people with rare and serious diseases.

A Legacy of Innovation and Excellence

CSL Behring's history dates back to the early 20th century, when Emil von Behring, a Nobel Prize winner, discovered diphtheria antitoxin, a groundbreaking treatment that saved countless lives. This discovery laid the foundation for the company's commitment to plasma-derived therapies.

Global Presence, Local Impact

With its headquarters in King of Prussia, Pennsylvania, CSL Behring has a global presence that spans over 30 countries. The company's manufacturing facilities are strategically located around the world to ensure a reliable supply of plasma-derived therapies to patients in need.

Commitment to Research and Development

CSL Behring is at the forefront of research and development in the field of plasma-derived therapies. The company invests heavily in research to discover and develop new treatments for rare and serious diseases. CSL Behring's research efforts have led to the development of innovative therapies that have transformed the lives of patients worldwide.

Collaboration for a Healthier Future

CSL Behring recognizes the importance of collaboration in advancing medical research and improving patient outcomes. The company actively collaborates with leading academic institutions, research centers, and healthcare providers around the world to accelerate the development of new therapies and expand access to life-saving treatments.

Conclusion

CSL Behring's headquarters in King of Prussia, Pennsylvania, serves as the nerve center of a global biopharmaceutical company dedicated to providing innovative plasma-derived therapies to patients with rare and serious diseases. The company's commitment to research, collaboration, and patient-centric care has made it a leader in the industry and a beacon of hope for patients around the world.

FAQs:

1. What is CSL Behring's primary focus?

CSL Behring specializes in plasma-derived therapies, a unique and essential class of medicines used to treat rare and serious diseases.

2. Where is CSL Behring headquartered?

CSL Behring is headquartered in King of Prussia, Pennsylvania, United States, a location that facilitates global operations and collaboration.

3. What is CSL Behring's history?

The company's legacy dates back to the early 20th century, rooted in the groundbreaking work of Nobel Prize winner Emil von Behring, who discovered diphtheria antitoxin.

4. How extensive is CSL Behring's global presence?

CSL Behring operates in over 30 countries worldwide, ensuring a global reach and reliable supply of plasma-derived therapies to patients in need.

5. What is CSL Behring's commitment to research and development?

CSL Behring invests heavily in research and development to discover and develop innovative plasma-derived therapies, transforming the lives of patients with rare and serious diseases.